Background/aim: To investigate the utility of preoperative serum cancer antigen 125 (CA 125) levels in type 1 endometrial carcinoma (EC) as a marker for determining poor prognostic factors and survival. Material and methods: All patients with endometrial cancer, who had been treated between 2012 and 2020, were retrospectively reviewed, and finally, 256 patients with type 1 endometrium carcinoma were included in the study. The relationship between the clinicopathological characteristics, CA 125 level, and survival rates were analyzed. The cut-off value for the preoperative serum CA 125 level was defined as 16 IU/L. Results: The median serum CA 125 levels were significantly higher in patients with deep myometrial invasion, lymph node metastasis, lymphovascular space invasion, cervical stromal and adnexal involvement, advanced stage, positive peritoneal cytology, recurrence, and adjuvant therapy requirement. Serum CA 125 cut-off values determined according to clinicopathologic factors ranged from 15.3 to 22.9 IU/L (sensitivity 61%–77%, specificity 52%–73%). The disease-specific survival rate was significantly higher in patients with CA 125 levels < 16 IU/L (P = 0.047). Conclusion: The data showed that choosing a lower threshold value for the CA 125 level (16 IU/L) instead of 35 IU/L, could be more useful in type 1 EC patients with negative prognostic factors. Key words: Cancer antigen 125 (CA 125), cut-off value, endometrial carcinoma, prognosis, survival
|
Background/aim: To investigate the utility of preoperative serum cancer antigen 125 (CA 125) levels in type 1 endometrial carcinoma (EC) as a marker for determining poor prognostic factors and survival. Material and methods: All patients with endometrial cancer, who had been treated between 2012 and 2020, were retrospectively reviewed, and finally, 256 patients with type 1 endometrium carcinoma were included in the study. The relationship between the clinicopathological characteristics, CA 125 level, and survival rates were analyzed. The cut-off value for the preoperative serum CA 125 level was defined as 16 IU/L. Results: The median serum CA 125 levels were significantly higher in patients with deep myometrial invasion, lymph node metastasis, lymphovascular space invasion, cervical stromal and adnexal involvement, advanced stage, positive peritoneal cytology, recurrence, and adjuvant therapy requirement. Serum CA 125 cut-off values determined according to clinicopathologic factors ranged from 15.3 to 22.9 IU/L (sensitivity 61%–77%, specificity 52%–73%). The disease-specific survival rate was significantly higher in patients with CA 125 levels < 16 IU/L (P = 0.047). Conclusion: The data showed that choosing a lower threshold value for the CA 125 level (16 IU/L) instead of 35 IU/L, could be more useful in type 1 EC patients with negative prognostic factors. Key words: Cancer antigen 125 (CA 125), cut-off value, endometrial carcinoma, prognosis, survival
|
Objective: To analyze the histopathologic outcomes of patients with atypical glandular cells (AGC) in cervicovaginal cytology examinations.Material and Methods: Patients with AGC in cervicovaginal cytology were included in this study between March 2011 and March 2018 andpatient data were collected retrospectively among all cytology results. AGC classification of cervicovaginal cytology were based on the Bethesda2001 classification system.Results: The total prevalence of cervical epithelial cell abnormality and AGC were found as 4.2% and 0.2%, respectively, in the study cohort.AGC-favor neoplasia (AGC-FN) was the subgroup of AGC with the highest malignancy rate with 62.5% (p=0.06). The incidence of malignancy inthe postmenopausal group (33.3%) was detected higher than in the premenopausal group (8.3%) (p=0.07).Conclusion: The probability of malignancy in AGC-FN cytology is more commonly associated with malignancy in the postmenopausal group.Therefore, histopathologic examination is strongly recommended in these patients with AGC smears because of the high risk for malignancy inthis group. (J Turk Ger Gynecol Assoc 2020; 21: 102-6)
|
Objective: To evaluate the pathological and radiological features, immunohistochemical profile and treatment methods of primary male breastcarcinoma cases diagnosed at our center.Material and Method: The pathology archive between 2006 and 2019 was reviewed and the data of 27 male patients diagnosed as primary breastcancer were retrospectively evaluated.Results: The age of the patients ranged between 40-86 years. The left breast was involved in 17 patients. The mean tumor diameter was 2.35± 1.09 cm. Of the 27 cases, 8 were dead and 19 were alive. The mean follow-up duration was 37.45 ± 24.84 months. The mean estimated lifeexpectancy was 65±14.7 months. The most common complaint was a swelling in the breast. The time interval between the onset of complaintsand admittance to hospital ranged from three months to two years. The most common histopathological diagnosis was invasive carcinoma - nospecial type. The most common surgical procedure was mastectomy with lymph node dissection. Nine patients had metastatic lymph nodes. Interms of the hormone profiles, 24 were Estrogen receptor positive, 21 were Progesterone receptor positive and six were Her2/neu positive. Threepatients had triple-negative tumors.Conclusion: Male breast carcinoma is a rare disease but its frequency has been increasing recently. As breast cancer is more commonly attributedto women, the diagnosis is usually delayed until later stages in males. Public awareness should therefore be increased and breast cancer shouldbe considered in the differential diagnosis especially in the presence of breast swelling and complaints related to the breast skin so that theappropriate biopsy can be obtained without delay.
|
Primary breast sarcomas are very rare and account less than 1% of invasive breast carcinomas. Primary sarcomas of breast are leiomyosarcoma, angiosarcoma, liposarcoma, firosarcoma, rhabdomyosarcoma, malignant peripheral nerve sheath tumor and pleomorphic sarcoma. Recently, a newCD10 positive group of sarcoma was identifid. Thse tumors cannot be classifid as a soft tissue sarcoma and show diffse strong positive stainingpattern with CD10 (NSCD10). Herein we report clinical and morphological characteristics of two cases diagnosed with not otherwise specifid-typesarcoma with CD10 expression by histologically and immunohistochemical fidings with the literature. NSCD10 shows similarity with leiomyosarcoma and sarcomatoid-type metaplastic carcinoma histomorphologically among specifi sarcomas of breast. CD10 expression should be taken intoconsideration in the presence of not diagnosed and not specifid tumors and CD10 should be added to the immunohistochemical panel.
|
